Search bioRxiv⌕ Search

bioRxiv · 10.1101/789842

NeuroPycon: A free Python toolbox for fast multi-modal and reproducible brain connectivity pipelines

Abstract

Recent years have witnessed a massive push towards reproducible research in neuroscience. Unfortunately, this endeavor is often challenged by the large diversity of tools used, project-specific custom code and the difficulty to track all user-defined parameters. NeuroPycon is an open-source multi-modal brain data analysis toolkit which provides Python-based template pipelines for advanced multi-processing of MEG, EEG, functional and anatomical MRI data, with a focus on connectivity and graph theoretical analyses. Importantly, it provides shareable parameter files to facilitate replication of all analysis steps. NeuroPycon is based on the NiPype framework which facilitates data analyses by wrapping many commonly-used neuroimaging software tools into a common Python environment. In other words, rather than being a brain imaging software with is own implementation of standard algorithms for brain signal processing, NeuroPycon seamlessly integrates existing packages (coded in python, Matlab or other languages) into a unified python framework. Importantly, thanks to the multi-threaded processing and computational efficiency afforded by NiPype, NeuroPycon provides an easy option for fast parallel processing, which critical when handling large sets of multi-dimensional brain data. Moreover, its flexible design allows users to easily configure analysis pipelines by connecting distinct nodes to each other. Each node can be a Python-wrapped module, a user-defined function or a well-established tool (e.g. MNE-Python for MEG analysis, Radatools for graph theoretical metrics, etc.). Last but not least, the ability to use NeuroPycon parameter files to fully describe any pipeline is an important feature for reproducibility, as they can be shared and used for easy replication by others. The current implementation of NeuroPycon contains two complementary packages: The first, called ephypype, includes pipelines for electrophysiology analysis and a command-line interface for on the fly pipeline creation. Current implementations allow for MEG/EEG data import, pre-processing and cleaning by automatic removal of ocular and cardiac artefacts, in addition to sensor or source-level connectivity analyses. The second package, called graphpype, is designed to investigate functional connectivity via a wide range of graph-theoretical metrics, including modular partitions. The present article describes the philosophy, architecture, and functionalities of the toolkit and provides illustrative examples through interactive notebooks. NeuroPycon is available for download via github (https://github.com/neuropycon) and the two principal packages are documented online (https://neuropycon.github.io/ephypype/index.html. and https://neuropycon.github.io/graphpype/index.html). Future developments include fusion of multi-modal data (eg. MEG and fMRI or intracranial EEG and fMRI). We hope that the release of NeuroPycon will attract many users and new contributors, and facilitate the efforts of our community towards open source tool sharing and development, as well as scientific reproducibility.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Meunier, D., Pascarella, A., Altukhov, D., Jas, M., Combrisson, E., Lajnef, T., Bertrand-Dubois, D., Hadid, V., Alamian, G., Alves, J., Barlaam, F., Saive, A.-L., Dehgan, A., Jerbi, K.. 2019-10-02. NeuroPycon: A free Python toolbox for fast multi-modal and reproducible brain connectivity pipelines. https://doi.org/10.1101/789842

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Feasible closed-loop stimulation for neural latent dynamics control

Modern neuroscience benefits from powerful computational and experimental methods for studying neural populations, including latent dynamics models that predict behavior with few dimensions. But despite their explanatory utility, latent factors are seldom targeted explicitly with experimental perturbations, leaving causal relationships to behavior and inferred dynamical landscapes untested. A promising solution is closed-loop, multi-channel optogenetic control, which, when paired with model predictions, could steer neural trajectories in real time--a feat impossible for traditional, hand-designed stimulation. However, because closed-loop latent control has not been demonstrated in vivo, the hardware and software requirements remain unclear--particularly the necessary stimulation dimensionality and how limited resources such as implant volume and bandwidth should be allocated between stimulation and recording capabilities. Preliminary experiments would thus help guide ongoing technological development. As large-scale exploration of these design spaces in vivo is prohibitively expensive, we conducted a high-throughput simulation survey using biophysically grounded spiking neural networks. We found that low-dimensional actuation is sufficient: in the reference configuration, ~20% of the stimulation channels achieved ~85% of peak control performance, far fewer than the number of neurons. Furthermore, allocating channels roughly equally between stimulation and recording optimized behavioral control, whereas pairing many electrodes with a single light source--the prevailing practice in experimental labs--performed poorly. Even without heavily optimizing modeling or control, we obtained >60% tracking error reduction and >90% evoked behavior accuracy on average for optimal channel counts. These results held across extensive parameter variations, suggesting that closed-loop latent control is feasible with accessible channel counts and establishing design principles for future tool development and in vivo experiments.

neuroscience↗

Identification of Kinome Biomarkers and Therapeutic Rescue in cGMP-Linked Retinal Degeneration

Inherited retinal degenerations, such as Retinitis Pigmentosa (RP) and Leber's congenital amaurosis (LCA), are major causes of progressive and irreversible vision loss. The large number of genes associated with these disorders makes their clinical and molecular characterization difficult, while systemic biomarkers for disease progression or treatment response remain limited. These challenges were addressed by targeting cGMP-associated mechanisms shared by RP and LCA and integrating systemic biomarker profiling with retinal outcomes. Kinase activity analysis (kinome analysis) in peripheral blood mononuclear cells distinguished healthy and diseased states and captured therapy-associated signatures in rd10 mice treated with LP-CN03, a liposomal formulation of the cGMP analog CN03. This first systemic analysis in a therapeutically responsive animal model highlights kinome analysis as a potential translational readout. Given shared cGMP signaling in RP and AIPL1-associated LCA, LP-CN03's therapeutic potential was further evaluated in a new CRISPR-Cas9-generated Aipl1-/- mouse model. Treatment with LP-CN03 preserved retinal structure and function, as shown by electroretinography, longitudinal optical coherence tomography, fundus imaging, optomotor testing, and photoreceptor-specific gene expression. Together, these findings provide independent in vivo evidence for the neuroprotective effect of LP-CN03 in both cGMP-related RP and LCA, also highlighting the translational value of kinome profiling.

neuroscience↗

Shikonin alleviates bone cancer pain through suppression of spinal IGF2-associated p38 MAPK signaling

Background Bone cancer pain (BCP) is a debilitating complication of advanced cancer that substantially impairs physical function and emotional wellbeing. Current pharmacological treatments often provide incomplete analgesia and may be limited by adverse effects. Shikonin, a bioactive naphthoquinone derived from Lithospermum erythrorhizon, exhibits analgesic and anti inflammatory activities, but its effects and underlying mechanisms in BCP remain unclear. Methods A rat model of BCP was established by intratibial inoculation of luciferase labeled MADB106 cells. The analgesic and behavioral effects of intrathecal Shikonin were evaluated using mechanical and thermal nociceptive assays, CatWalk gait analysis, the open field test (OFT), elevated plus maze (EPM), light/dark box (LDB) test, and rotarod testing. Bioluminescence imaging and hematoxylin eosin staining were used to characterize tumor development and bone pathology. Spinal dorsal horn transcriptomic sequencing was performed to identify candidate molecular pathways. Western blotting, quantitative PCR, and ELISA were used to examine IGF2 associated p38 MAPK signaling and proinflammatory cytokines. The functional involvement of IGF2 and p38 associated signaling was further evaluated using intrathecal IGF2 siRNA and the p38 inhibitor Adezmapimod (SB203580). Results Intrathecal Shikonin produced dose and time dependent antinociceptive effects in BCP rats, with an estimated ED50 of 29.80 g/kg, and did not produce an apparent impairment of rotarod performance. Shikonin also improved gait abnormalities and pain related anxiety like behaviors. Transcriptomic analysis identified Igf2 as a candidate gene responsive to Shikonin treatment, and spinal IGF2 and p38 phosphorylation were increased during BCP development. Shikonin significantly reduced IGF2 expression and p38 phosphorylation in the spinal dorsal horn, accompanied by decreased IL 6, IL 1{beta};, and TNF ; expression in spinal tissue. IGF2 knockdown reproduced the analgesic and behavioral effects of Shikonin and reduced p38 phosphorylation, whereas p38 inhibition reproduced key behavioral effects without a marked change in IGF2 expression. Combined treatment with Shikonin and either IGF2 knockdown or p38 inhibition produced no significant additional behavioral benefit. Conclusion Intrathecal Shikonin alleviates nociceptive hypersensitivity, functional impairment, and pain related anxiety like behaviors in rats with MADB106 induced BCP. The phenocopying and non additive effects of IGF2 knockdown and p38 inhibition support the involvement of an IGF2 associated p38 MAPK signaling axis in the analgesic actions of Shikonin.

neuroscience↗